Akèy › Trombositemi Esansyèl › Massachusetts
Etid klinik pou Trombositemi Esansyèl nan Massachusetts
4 etid pou Trombositemi Esansyèl ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (Bidmc), Boston
- University of Massachusetts Medical School, Worcester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07623200Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT07441694A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 17, 2026 · NCT06034002Ruxolitinib in Thrombocythemia and Polycythemia Vera
- Massachusetts General Hospital, Boston
- Beth-Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jan 8, 2026 · NCT04644211Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.